14. Recombinant MVA vaccines: Optimization, Preclinical, and Product Development

  1. W. John W. Morrow PhD, DSc, FRCPath2,
  2. Nadeem A. Sheikh PhD3,
  3. Clint S. Schmidt PhD4 and
  4. D. Huw Davies PhD5
  1. Yper Hall BSc and
  2. Miles W. Carroll PhD

Published Online: 20 JUN 2012

DOI: 10.1002/9781118345313.ch14

Vaccinology: Principles and Practice

Vaccinology: Principles and Practice

How to Cite

Hall, Y. and Carroll, M. W. (2012) Recombinant MVA vaccines: Optimization, Preclinical, and Product Development, in Vaccinology: Principles and Practice (eds W. J. W. Morrow, N. A. Sheikh, C. S. Schmidt and D. H. Davies), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118345313.ch14

Editor Information

  1. 2

    Seattle, WA, USA

  2. 3

    Dendreon Corporation, Seattle, WA, USA

  3. 4

    NovaDigm Therapeutics, Inc., Grand Forks, ND, USA

  4. 5

    University of California at Irvine, Irvine, CA, USA

Author Information

  1. Microbiology Division, Health Protection Agency, Porton Down, UK

Publication History

  1. Published Online: 20 JUN 2012
  2. Published Print: 3 AUG 2012

ISBN Information

Print ISBN: 9781405185745

Online ISBN: 9781118345313

SEARCH

Keywords:

  • viral vector;
  • vaccinia virus;
  • MVA;
  • recombinant;
  • vaccine;
  • manufacture;
  • clinical;
  • development

Summary

Modified vaccinia Ankara (MVA) virus is a highly attenuated, replication defective strain of vaccinia virus with attributes of an optimal viral delivery system, including large capacity for foreign DNA, proven clinical safety, and ability to induce potent and long-lasting humoral and cell-mediated immune responses, which can be further complemented in heterologous prime-boost regimens. Efficacy of recombinant MVA (rMVA) -based vaccines has been demonstrated in numerous preclinical and clinical studies against a range of targets, including HIV, malaria, tuberculosis, and an array of tumor-associated antigens. Recombinant MVA-based products can be rapidly constructed and are relatively inexpensive to manufacture, and the path to regulatory approval is well established. Provided novel rMVA are optimized at the preclinical stage to ensure efficacy, stability, a smooth regulatory path, and effective intellectual property strategy, they can be rapidly developed for clinical applications.